<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-38 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-38</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-38</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <p><strong>Paper ID:</strong> paper-d20fe195f004827b472ab806e95711ef06d92f4d</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/d20fe195f004827b472ab806e95711ef06d92f4d" target="_blank">Cancer and Dementia: It’s Complicated</a></p>
                <p><strong>Paper Venue:</strong> Alzheimer Disease and Associated Disorders</p>
                <p><strong>Paper TL;DR:</strong> Multiple potential lines of evidence must be disentangled to investigate underlying mechanisms, the end-game being to develop and to test potential prevention and treatment strategies.</p>
                <p><strong>Cost:</strong> 0.013</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e38.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e38.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AD-cancer inverse</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Alzheimer's disease versus various cancers (inverse association)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Epidemiologic evidence in this review shows a consistent inverse association between Alzheimer’s disease (AD) and overall cancer risk (stronger for certain cancer types such as smoking-related cancers and non-melanoma skin cancer), supported by multiple population-based cohorts and registry studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Cancer and Dementia: It's Complicated</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>overall cancer (with emphasis on smoking-related cancers: oral cavity, pharynx, larynx, esophagus, stomach, pancreas, lung, cervix, kidney) and non-melanoma skin cancer; epithelial cancers (colorectal, lung) also highlighted</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Alzheimer's disease (AD)</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>inverse correlation (reduced cancer incidence or mortality among people with AD and reduced AD incidence among cancer survivors); magnitude varies by study and cancer type</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>Multiple studies cited: atom bomb survivor prevalence study OR 0.3 (inverse, AD vs cancer); death-certificate cohort OR 0.395 (less cancer listed among AD deaths); Spanish population RR 0.53 (reduced cancer mortality in AD); ADRC case-control HR ~0.39 (reduced cancer risk in AD) and HR ~0.4 (reduced AD after cancer history); ADNI: history of cancer inversely associated with AD at baseline and later AD onset (independent of APOE*4); Framingham: survivors of smoking-related cancers HR 0.67 for incident AD; Framingham nested case-control incident AD cases had HR 0.39 of subsequent cancer; Northern Italy (Milan) RR 0.57 (reduced cancer in AD) and RR 0.65 (reduced AD in cancer); Sweden registry RR 0.60 (reduced dementia 9–45 months before cancer); Taiwan NHI SIR overall cancer 0.88 and lung cancer SIR 0.75 in AD patients; Einstein Aging non-melanoma skin cancer HR 0.21 reduced AD risk.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Multiple, non-mutually exclusive mechanisms proposed: (1) opposing regulation of apoptosis vs proliferation (genes/pathways that favor cell proliferation in cancer but apoptosis or hyperactive cell-death signaling in neurons), (2) immune-related mechanisms including immunosenescence, altered immune surveillance and inflammasome-mediated neuroinflammation (e.g., NLRP3 activation by Aβ), (3) shared genetic pathways with differential regulation (e.g., PIN1 overexpressed in some cancers but required for tau phosphorylation in AD; PARK2 as tumor suppressor and involved in neuronal homeostasis), (4) altered ABC transporter activity at the blood-brain barrier in cancer survivors leading to extrusion of amyloid-beta, (5) treatment effects and exposures (some cancer drugs may reduce amyloid in animal models; conversely, under-ascertainment and survivor/competing-risk biases considered but argued insufficient to fully explain the signals).</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td>PIN1 (peptidyl-prolyl isomerase NIMA-interacting 1) — overexpressed in some cancers; implicated in tau phosphorylation in AD; PARK2 (parkin) — E3 ubiquitin ligase, tumor suppressor candidate and linked to neuronal homeostasis; p53 — tumor suppressor implicated in cell-cycle/apoptosis and discussed as relevant to both cancer and neurodegeneration; Wnt pathway genes — involved in proliferative signaling and implicated in AD; APP (amyloid precursor protein) — overexpressed in Down syndrome with links to AD and leukemia (noted); APOE referenced in therapeutic context (bexarotene studies).</td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td>Beta-amyloid (Aβ) — central to AD pathology and implicated in immune interactions (toxic to NK cells); tau — phosphorylation regulated in part by PIN1; ABC transporters — implicated in extrusion of Aβ at the BBB; inflammasome components (NLRP3) — mediate innate immune responses in CNS; synucleins (alpha- and gamma-synuclein) mentioned as dual-role proteins linking neurodegeneration and cancer; cyclin-E — cell-cycle protein implicated in synaptic plasticity and memory; proteasome components discussed in conceptual mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td>Apoptosis vs cell proliferation balance; cell-cycle regulation and aberrant cell-cycle activation in neurons; inflammasome / innate immune activation (NLRP3); Wnt signaling; p53-mediated DNA damage response and apoptosis; ubiquitin–proteasome system; microRNA-regulated pathways (differential miRNA expression overlapping cancer and AD); bioenergetics / oxidative stress / DNA repair pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Opposing phenotypes of cell proliferation (tumorigenesis) versus cell death/apoptosis (neurodegeneration); immunosenescence and chronic inflammation; protein aggregation (Aβ, tau) and impaired proteostasis; altered BBB transporter activity affecting Aβ clearance; aberrant cell-cycle re-entry in neurons; oxidative stress and DNA damage/repair dysregulation.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>Epidemiologic longitudinal cohorts (Framingham prospective 22-year data showing HR 0.67 for AD after smoking-related cancer and nested HR 0.39 for cancer after AD), multiple large registry studies (Sweden, Northern Italy, Taiwan) and ADNI imaging/cancer-history associations; autopsy study reported fewer cancer deaths among AD patients; animal studies: NLRP3 activation shown to contribute to pathology in APP/PS1 mouse models of AD; oncology drugs in mice (bexarotene cleared Aβ and improved cognition in AD mouse models; chronic carmustine reduced plaque burden) provide mechanistic lead that cancer drugs can affect AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>Potential biases (survival/competing risks, ascertainment) could partially explain associations but Framingham sensitivity analyses argue against full explanation; treatment-related cognitive effects (chemotherapy 'chemo-brain') sometimes reported (mixed evidence); estrogen therapy: timing-dependent effects (neuroprotective if long-term earlier use, but increased dementia risk with late-life use), which complicates cancer-treatment interpretations; not all cancers or cancer types show the same inverse effect (heterogeneity).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review article synthesizing epidemiological studies, registries, cohort analyses, and mechanistic literature (epidemiological synthesis / narrative review)</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>A consistent inverse epidemiologic association exists between Alzheimer’s disease and several cancers—particularly smoking-related cancers and non-melanoma skin cancer—supported by multiple cohort and registry studies and animal-model leads; mechanisms proposed include opposing regulation of proliferation versus apoptosis, shared genetic pathways (PIN1, PARK2, p53, Wnt), immune/inflammasome processes, and possible treatment effects, but causality remains unresolved and requires mechanistic and prospective biomarker studies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Cancer and Dementia: It’s Complicated', 'publication_date_yy_mm': '2015-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e38.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e38.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PD-cancer mixed</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Parkinson's disease and cancer (mixed inverse and positive associations depending on cancer type)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Parkinson’s disease (PD) shows an overall reduced risk of many cancers in multiple studies, but consistent positive associations with melanoma and certain skin cancers (and selected increases in breast/prostate in some cohorts), indicating a heterogeneous relationship by cancer type.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Cancer and Dementia: It's Complicated</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>overall cancers (many types), non-melanoma skin cancer, malignant melanoma, colorectal, lung/bronchus, pancreas, stomach, female breast, prostate</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Parkinson's disease (PD)</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>mixed: overall inverse correlation for many cancers (reduced risk), but positive correlations (increased risk) with melanoma and some skin cancers and in some cohorts breast and prostate cancer are elevated</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>Meta-analysis of 29 studies (107,598 subjects) pooled RR for overall cancer in PD = 0.73; non-skin cancers RR = 0.69; smoking-related cancers RR = 0.61; smoking-unrelated cancers RR = 0.76. Danish National Hospital Register: SIR overall cancer 0.86, smoking-related cancers SIR 0.65, smoking-unrelated SIR 0.79, but malignant melanoma SIR 1.41, non-melanoma skin cancer SIR 1.29, female breast cancer SIR 1.17. Utah Cancer Registry: reduced risks for colorectal RR 0.55, lung/bronchus RR 0.22, pancreas RR 0.26, stomach RR 0.22, but elevated melanoma RR 1.95 and elevated prostate RR 1.71.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Shared genetic predispositions (e.g., PARK2 involvement) and differential regulation of cell survival/proliferation pathways; possible role of environmental exposures (smoking lowers PD risk and increases smoking-related cancer risk) and immune surveillance differences; paraneoplastic autoimmunity and shared antigens implicated in some associations (e.g., melanoma-PD link). The review suggests genes and pathways that favor apoptosis in neurons vs proliferation in cancers (opposite ends of a spectrum) and mentions synucleins as proteins with dual relevance.</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td>PARK2 (parkin) — E3 ubiquitin ligase implicated in PD and suggested tumor suppressor role; other genes/pathways discussed generally include p53 and Wnt; synuclein genes (SNCA encoding alpha-synuclein and SNCG encoding gamma-synuclein) noted as linking PD and some cancers (gamma-synuclein in breast/colorectal cancer).</td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td>Alpha-synuclein (SNCA) — central to PD pathogenesis and discussed as 'two-edged sword'; gamma-synuclein — implicated in certain cancers; cyclin-E and proteasome system mentioned as shared cellular machinery potentially linking PD and cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td>Ubiquitin–proteasome system (PARK2/parkin), cell-cycle regulation, apoptosis vs proliferation balance, immune surveillance, synuclein-related pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Dysregulated proteostasis and ubiquitination, aberrant cell-cycle control, differential apoptosis/proliferation, immune surveillance differences, and protein aggregation (alpha-synuclein) in neurons.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>Epidemiologic cohort and registry data (Mayo Clinic historical cohort, Danish register, Utah registry, meta-analysis) show consistent patterns of reduced risk for many cancers but elevated melanoma risk; pedigree/population studies (Utah) showed shared familial risks for PD and certain cancers, suggesting genetic predisposition; mechanistic animal/model evidence is less direct in this review but genetic links (PARK2) are discussed.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>Robust counterexample is the repeatedly replicated positive association between PD and malignant melanoma (and sometimes other skin cancers), and some reports of elevated breast and prostate cancer in PD; levodopa treatment was historically suggested to raise melanoma risk but more recent studies do not support levodopa as causal.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review article summarizing epidemiological cohort, registry, pedigree, and meta-analytic evidence (epidemiological synthesis / narrative review)</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Parkinson’s disease is generally associated with reduced risk of many cancers, particularly smoking-related cancers, but shows a robust and repeatedly replicated positive association with melanoma (and some skin cancers), indicating disease- and cancer-type-specific relationships likely driven by a mix of genetic, immune, and exposure-related mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Cancer and Dementia: It’s Complicated', 'publication_date_yy_mm': '2015-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e38.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e38.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ND-cancer meta-signal</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Inverse cancer comorbidity across multiple neurodegenerative disorders (meta-analysis signal)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A pooled/meta-analytic signal across neurodegenerative disorders shows reduced co-occurring cancer incidence overall, with particularly strong inverse effect sizes reported for Alzheimer's disease and Huntington's disease in included studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Cancer and Dementia: It's Complicated</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>overall cancer incidence across many cancer types as aggregated in meta-analyses</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Multiple neurodegenerative disorders aggregated (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease)</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>inverse correlation when aggregated across disorders (pooled effect sizes <1), with heterogeneity between disorders (AD strongest inverse, PD moderate inverse, others variable)</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>Meta-analysis cited (Catala-Lopez et al.) of 50 observational studies with 577,013 participants reported pooled effect sizes: all neurodegenerative disorders ES 0.80; AD ES 0.32; PD ES 0.83; multiple sclerosis ES 0.91; Huntington's disease ES 0.53 — indicating reduced cancer incidence overall and especially in AD and Huntington's disease.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>High-level mechanisms proposed include inverse regulation of cell proliferation versus cell death across disorders, shared transcriptomic signatures of inverse comorbidity (genes upregulated in one condition and downregulated in the other), and immune/inflammation differences; microRNA differential expression producing inverse regulation of proliferation and apoptosis is also suggested.</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td>General transcriptomic findings discussed (from cited studies) implicate multiple genes and pathways showing inverse regulation; specific genes mentioned in the review with relevance to inverse comorbidity include PIN1, PARK2, p53, Wnt pathway genes, and APP in context of Down syndrome (as examples of genes with roles in both cancer and neurodegeneration).</td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td>Proteins implicated broadly include Aβ and tau (AD), synucleins (PD/cancer links), inflammasome components (NLRP3), and proteasome components; microRNA-regulated protein networks also implicated.</td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td>Transcriptomic inverse regulation, cell-cycle control, apoptosis, inflammation/immune activation (inflammasomes, immunosenescence), DNA damage/repair, bioenergetics/oxidative stress, ubiquitin–proteasome system.</td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Opposite ends of a spectrum from abnormal cell death/apoptosis (neurodegeneration) to abnormal cell proliferation (cancer); altered immune surveillance and chronic inflammation; disrupted proteostasis and DNA repair mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>Large-scale meta-analyses and transcriptomic meta-analyses are cited (e.g., Catala-Lopez meta-analysis and PLoS Genetics transcriptomic meta-analysis) showing aggregated inverse comorbidity signals and molecular evidence from transcriptomic datasets indicating inverse expression patterns between CNS disorders and cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>Heterogeneity across disorders and cancer types: PD shows both inverse and positive associations depending on cancer type (melanoma positive), multiple sclerosis shows near-null pooled ES, and individual study heterogeneity and potential biases (ascertainment, survival, confounding) limit interpretation.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing and synthesizing findings from meta-analyses, population registries, and transcriptomic studies (review/meta-analysis summary)</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Meta-analytic and transcriptomic evidence points to an overall inverse comorbidity between cancer and several central nervous system disorders—most striking for AD—suggesting shared but oppositely regulated molecular pathways (e.g., proliferation vs apoptosis), though heterogeneity and exceptions (e.g., PD–melanoma) indicate complexity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Cancer and Dementia: It’s Complicated', 'publication_date_yy_mm': '2015-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Inverse Association between Cancer and Neurodegenerative Disease: review of the epidemiologic and biologic evidence <em>(Rating: 2)</em></li>
                <li>Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies <em>(Rating: 2)</em></li>
                <li>Inverse Association between Cancer and Alzheimer's Disease: Results from the Framingham Study <em>(Rating: 2)</em></li>
                <li>Inverse occurrence of cancer and Alzheimer disease: a population-based study <em>(Rating: 2)</em></li>
                <li>Low cancer rates among patients with dementia in a population-based register in Sweden <em>(Rating: 2)</em></li>
                <li>Parkinson's disease and cancer risk: a systematic review and meta-analysis <em>(Rating: 2)</em></li>
                <li>Shared predispositions of parkinsonism and cancer. A population-based pedigree study <em>(Rating: 1)</em></li>
                <li>NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice <em>(Rating: 2)</em></li>
                <li>ApoE-Directed Therapeutics Rapidly Clear b-Amyloid and Reverse Deficits in AD Mouse Models <em>(Rating: 2)</em></li>
                <li>Striking reduction of amyloid plaque in an Alzheimer’s mouse model after chronic administration of carmustine <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>